Brief: Zynerba Pharmaceuticals Inc - Plans To Focus Development Of Zygel In FXS, ASD and 22q

Zynerba Pharmaceuticals

04/01/2022 21:21

Jan 4 (Reuters) - Zynerba Pharmaceuticals Inc  ZYNE.O :
    * ZYNERBA PHARMACEUTICALS INC - PLANS TO FOCUS DEVELOPMENT
OF
ZYGEL IN FXS, ASD AND 22Q
    * ZYNERBA PHARMACEUTICALS INC - PLANS TO INITIATE PHASE 3
TRIAL
WITH ZYGEL IN ASD IN SECOND HALF OF 2022
    * ZYNERBA PHARMACEUTICALS INC - DECISION HAS BEEN MADE TO
NOT MOVE
FORWARD IN DEE AT THIS TIME
    * ZYNERBA PHARMACEUTICALS INC - CONTINUES TO EXPECT TOPLINE
RESULTS FROM RECONNECT IN SECOND HALF OF 2023
    * ZYNERBA PHARMACEUTICALS - PLANS TO ADVANCE ITS PROGRAM IN
ASD
WITH TWO PHASE 3 TRIALS, FIRST OF WHICH IS EXPECTED TO START IN
SECOND HALF OF 2022
    * ZYNERBA PHARMACEUTICALS - BELIEVES $75.6 MILLION OF CASH,
CASH
EQUIVALENTS AS OF SEPT 30, 2021 ARE SUFFICIENT TO FUND
OPERATIONS, CAPITAL REQUIREMENTS INTO H2 2023

Source text for Eikon:  ID:nGNX8p6RKk 
Further company coverage:  ZYNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))